98%
921
2 minutes
20
Key Points: Glypican-4 (GPC4) levels were strongly elevated in incident dialysis patients compared with individuals without evidence of kidney disease. Circulating GPC4 was significantly correlated with various parameters linked to adverse conditions commonly present in incident dialysis patients. No association was found between GPC4 and all-cause mortality in incident dialysis patients.
Background: Glypican-4 (GPC4) is a cell surface heparan sulfate proteoglycan that can be released into circulation under various clinical conditions. Elevated levels of circulating GPC4 have recently been associated with reduced kidney function and an increased risk of all-cause mortality across different patient populations. The potential of circulating GPC4 for assessing disease status or prognosis in patients with ESKD has not yet been explored and was addressed in this study.
Methods: This study included 187 patients starting chronic dialysis treatment. In addition, 108 control subjects with normal or mildly reduced kidney function, matched for sex and age, were included in the study. The median follow-up time of incident dialysis patients was 3.8 years. Blood samples were collected immediately before initiation of dialysis. Serum GPC4 levels were determined using an enzyme-linked immunosorbent assay.
Results: Serum GPC4 levels were approximately ten-fold higher in incident dialysis patients compared with controls, demonstrating excellent classification ability to distinguish between the two groups. Furthermore, circulating GPC4 was significantly positively correlated with creatinine and phosphate and significantly negatively correlated with estimated GFR, hemoglobin, erythrocytes, calcium, and cholinesterase in incident dialysis patients. There was no significant association between GPC4 levels and all-cause mortality in patients starting dialysis.
Conclusions: GPC4 levels were markedly elevated in patients initiating dialysis and were linked with several pathophysiologic characteristics commonly observed in ESKD. However, our findings did not indicate that elevated serum GPC4 levels serve as a significant predictor of all-cause mortality in this patient population.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12233845 | PMC |
http://dx.doi.org/10.34067/KID.0000000744 | DOI Listing |
Kidney360
March 2025
Vorarlberg Institute for Vascular Investigation and Treatment, Feldkirch, Austria.
Key Points: Glypican-4 (GPC4) levels were strongly elevated in incident dialysis patients compared with individuals without evidence of kidney disease. Circulating GPC4 was significantly correlated with various parameters linked to adverse conditions commonly present in incident dialysis patients. No association was found between GPC4 and all-cause mortality in incident dialysis patients.
View Article and Find Full Text PDFJ Mol Med (Berl)
April 2025
Vorarlberg Institute for Vascular Investigation & Treatment, (VIVIT), Feldkirch, Austria.
Glypican 4 (GPC4), a member of the cell surface heparan sulfate proteoglycan family, plays a crucial role in regulating various cell signaling and developmental processes. Its ability to be released from the cell surface into the bloodstream through shedding makes it a promising blood-based biomarker in health and disease. In this context, circulating GPC4 has been initially proposed as an insulin-sensitizing adipokine being linked with various conditions of insulin resistance.
View Article and Find Full Text PDFPharmgenomics Pers Med
July 2024
Department of General Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, People's Republic of China.
Background: Obesity is reaching epidemic proportions in the developed world. The biosynthesis and degradation of human glycoproteins take place at the highest level in the liver. However, the association between glycosylation and the factors affecting obesity and metabolism-associated steatohepatitis (MASH) is still unclear.
View Article and Find Full Text PDFBiochimie
August 2024
Stem Cell and Neurogenesis Group, Genomics Research Centre, Centre for Genomics and Personalised Health, School of Biomedical Sciences, Queensland University of Technology, Australia; ARC Training Centre for Cell and Tissue Engineering Technologies, Queensland University of Technology (QUT), Austral
Stem cell therapies hold promise in addressing the burden of neurodegenerative diseases with human embryonic neural stem cells (hNSC-H9s) and bone marrow-derived human mesenchymal stem cells (hMSCs) as viable candidates. The induction of hMSC neurospheres (hMSC-IN) generate a more lineage-restricted common neural progenitor-like cell population, potentially tunable by heparan sulfate proteoglycans (HSPGs). We examined CpG (5 mC) site methylation patterns using Illumina Infinium 850 K EPIC arrays in hNSC-H9, hMSCs and hMSC-IN cultures with HSPG agonist heparin at early and late phases of growth.
View Article and Find Full Text PDFInt J Mol Sci
April 2024
Department of Experimental Medical Science, Glycobiology Group, Lund University, Biomedical Center A13, SE-221 84 Lund, Sweden.
Glypicans are linked to various aspects of neoplastic behavior, and their therapeutic value has been proposed in different cancers. Here, we have systematically assessed the impact of GPC4 on cancer progression through functional genomics and transcriptomic analyses across a broad range of cancers. Survival analysis using TCGA cancer patient data reveals divergent effects of expression across various cancer types, revealing elevated expression levels to be associated with both poor and favorable prognoses in a cancer-dependent manner.
View Article and Find Full Text PDF